消化道狭窄的内镜治疗课件.ppt
《消化道狭窄的内镜治疗课件.ppt》由会员分享,可在线阅读,更多相关《消化道狭窄的内镜治疗课件.ppt(51页珍藏版)》请在淘文阁 - 分享文档赚钱的网站上搜索。
1、消化道狭窄的内镜治疗病理类型病理类型qq我国我国我国我国 鳞癌为主鳞癌为主鳞癌为主鳞癌为主 97.6%97.6%上上上上1/31/3段段段段 8.8%8.8%中中中中1/31/3段段段段 65.9%65.9%下下下下1/31/3段段段段 25.3%25.3%qq西方国家西方国家西方国家西方国家 以下段食管为主、主要为腺癌(以下段食管为主、主要为腺癌(以下段食管为主、主要为腺癌(以下段食管为主、主要为腺癌(6060以上)以上)以上)以上)食管癌的治疗食管癌的治疗(强调早期发现、早期诊断、早期治疗)手术治疗手术治疗 -姑息性手术姑息性手术 -根治性手术根治性手术内镜下治疗内镜下治疗 -食管扩张,食
2、管支架取代传统的旁路手术食管扩张,食管支架取代传统的旁路手术 -内镜下电灼切除、内镜下电灼切除、Nd:YAG激光切除、激光切除、光动力疗法等光动力疗法等化疗:化疗:5-Fu和顺铂为主和顺铂为主放疗:外放射为主放疗:外放射为主以手术为主的综合治疗以手术为主的综合治疗手术适应证早期食管癌早期食管癌中期(中期()、中下段食管癌病变在)、中下段食管癌病变在5cm内,上段在内,上段在3cm内,全身情况好者内,全身情况好者中期(中期()、病变在)、病变在5cm以上,无明显远处转移,以上,无明显远处转移,全身条件允许,可采用术前放化疗与手术综合疗法全身条件允许,可采用术前放化疗与手术综合疗法放射治疗后复发,
3、病变范围尚不大,无远处转移,放射治疗后复发,病变范围尚不大,无远处转移,全身情况良好者全身情况良好者 手术禁忌证手术禁忌证食管癌病变广泛或累及邻近器官如气管、食管癌病变广泛或累及邻近器官如气管、肺、纵隔等者肺、纵隔等者已有锁骨上窝淋巴结等远处转移者已有锁骨上窝淋巴结等远处转移者有严重心、肺或肝功能不全者有严重心、肺或肝功能不全者严重恶病质者严重恶病质者Surgical resection is the only curative treatment optionfor invasive esophageal cancer.However,despite carefulstaging and a
4、dvances in adjuvant therapy and surgicaltechniques,5-year survival rates rarely exceed 40%.1,2Many patients present with locoregional recurrence anddistant metastasis within 2 years after curative esophagectomy.3 Treatment of patients with local disease recurrenceaims at relieving dysphagia食管气管瘘金属支架
5、置放术复查碘油造影未见造影剂瘘出。Esophageal diseases and types of SEMS used UU CU E GZ WEsophageal carcinoma Cervical(n=14)7 7 Thoracic(n=93)31 47 7 3 5 G-E junction(n=79)44 26 2 7 Locally recurrent carcinoma 12 36 (n=48)Achalasia(n=8)4 4 UU,Uncovered Ultraflex(Boston Scientific,Boston,Mass.);CU,covered Ultraflex(B
6、oston Scientific);E,Esophacoil(Instent Inc.,Eden Prarie,Minn.);GZ,Gianturco Z-stent(Cook Inc.,Bloomington,Ind.);W,Wallstent(Boston Scientific).Factors that may predispose to esophageal stent migration:multivariate analysis N Migration(%)p value Gender Female 58 8/13(61.5)0.0038Stricture TC 80 2/13(1
7、5.4)0.954 GEJ 67 9/13(11.4)0.017 EAC 8 2/13(25)0.625Previous therapy S+B 4 2/13(15.4)0.997 R 10 2/13(15.4)0.997Dilation 10 mm 24 6/13(46.1)0.000Stent GZ 3 2/13(15.4)0.719 E 12 4.13(30.7)0.104 UU 87 4/13(30.7)0.169 CU 95 3/13(23.0)0.166TC,Esophageal thoracic carcinoma;GEJ,carcinoma of the gastroesoph
8、ageal junction;EAC,esophageal achalasia;S+B,surgery&balloon dilation;R,radiotherapy;GZ,Gianturco Z-stent;E,Esophacoil;UU,uncovered Ultraflex;CU,covered Ultraflex(Gastrointest Endosc 2001;53:96-97.)Esophageal stents for malignant strictures close to the upper esophageal sphincterGastrointest Endosc 2
9、007;66:1082-90Esophageal stents for the palliation of malignant dysphagia and fistula recurrence after esophagectomyLuminal patency.The median survival time afterstenting for all patients with stenosis was 70 days(range 1day to 34 months).Stent insertion was technically successful in all but 1 patie
10、nt(98%)(Fig.1).Median duration of primary stent patency was 56 days(range 1 day to 33 months)(Fig.2).A total of 20 episodes of stent dysfunction occurred in 18(27%)of 66 patients at a median of 38 days post-SEMS insertion(range 2-406 days).Stent dysfunction was caused by tissue in-or overgrowth(n 8)
11、,stent migration(n 9),and food impaction(n 3).Tissue in-and overgrowth occurred at a median of 119 days post-SEMS insertion(range 33297 days);5 patients were successfully treated with a second SEMS.Six(24%)of 25 fully covered stents versus 3(7%)of 41 partially covered SEMS migrated(P .07)at a median
12、 time interval of 66 days after SEMS insertion(range 12-406 days).Of these patients,6 patients required a second SEMS.Food bolus impaction occurred in 3(20%)patients at a median time interval of 11 days after SEMS insertion;all 3 were successfully cleared endoscopically.Insertion of a second SEMS wa
13、s successful in all patients(100%).Median patency of these stents was 59 days(range 5286 days)Fistula sealing.The median survival time of patients with malignant fistula caused by tumor recurrence was 73 days(range 10 days to 91 months).The coated segment of the stent effectively sealed fistulae in
14、all but 1 patient(93%).This patient was successfully treated with a second stent.Stent dysfunction occurred in 6(40%)of 15 patients.In 5(33%)patients,additional stents were successfully inserted to manage stent migration(n 4)and persistent leakage during stent treatment(n 1).Two(22%)of 9 fully cover
15、ed stents versus 2(33%)of 6 partially covered SEMSs migrated at a median time interval of 5 months post-SEMS insertion(range 5 days to 11 months).Food bolus impaction occurred in 1 patient 17 days post-SEMS insertion,this patient was also successfully treated endoscopicallyby stent clearance.Overall
16、 complications Mild complications after stent placement occurred in 7(9%)patients including retrosternal pain and symptomatic gastroesophageal reflux.Major complications occurred in 9(11%)patients.Stridor developed immediately after insertion in 3 patients with a lesion within 4 cm of the upper esop
17、hageal sphincter.In all 3 patients,the stent was removed,and they were managed conservatively.Three patients had an upper GI hemorrhage from the tumor site at a median time interval of 26 days after SEMS insertion(range 11 days to 10 months).The bleeding subsided spontaneously in 1 of these patients
18、;the other 2 patients died of the persistent bleeding.An esophageal fistula developed during stent treatment in 2 patients,both of which were located at the distal funnel of the partially covered stent at a median time interval of 48 days post-SEMS insertion.These wall defects were successfully seal
19、ed with an additional stent.One patient had stent-induced ulceration after stent migration at 7 months after SEMS insertion and required endoscopic stent extraction.SEMS placement in recurrent esophageal cancer after surgical resection offers adequate palliation by relieving dysphagia and sealing of
20、f esophageal respiratory fistula.Therefore,in these patients who have a relatively short life expectancy,the implantation of SEMSs to should be considered the treatment of choiceEsophageal respiratory fistulae occur in 5%to 10%of patients with esophageal cancer.In our series,19%of patients with recu
21、rrent cancer after gastric tube interposition presented with a fistula.This represents a devastating complication leading to recurrent pulmonary infections and the inability to eat or even swallow saliva.This condition is associated with a very high short-term mortality rate.The technical success of
22、 fistula sealing by SEMSs was 93%,which is within the range of the 80%to 100%reported by other series.In the majority of patients with cancer recurrence after esophagectomy,the fistula or stenosis is located close to the upper esophageal sphincter.At this location,SEMS placement may cause foreign-bo
23、dy sensation,tracheal compression,or respiratory fistula.It has been hypothesized that stents should have a body diameter of 18 mm or less to avoid these complications.In our series,however,stridor developed in 3(4%)patients and a fistula developed in 2(2%)patients after stent placement,despite the
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 消化道 狭窄 治疗 课件
限制150内